Samareh Azeredo da Silveira
Managing Director
Samareh is an early-stage drug development specialist. In 2007, she co-founded LASCCO SA, a virtual incubator dedicated to the identification of discovery-stage pharmaceuticals and diagnostics. Since then, she focused on the development of breakthrough technologies in the fields of critical care and infectious diseases. From 2011 to 2018, she was a partner at Sepstone Diagnostics, a spin-off of LASCCO, where she outlicensed a sepsis diagnostic technology to several industrial partners. She holds a PhD in Neurosciences from Ecole Polytechnique Fédérale de Lausanne (EPFL), and authored numerous publications and opinion reviews
Frédéric Lajaunias
Managing Director
Frédéric has over 10 years of experience in early stage development. In 2007, he co-founded LASCCO SA, a biomedical technology development company focusing on discovery-stage pharmaceuticals and diagnostics. Prior to founding LASCCO, Frédéric served at Abbott Laboratories as manager for the Swiss virology division. Before that, he carried out a post-doctoral work at the Geneva University Hospital studying autoimmune disorders.Frédéric holds a PhD in biology (immunology), from the University of Paris VII, and an MBA with a specialization in Entrepreneurship from the University of Geneva.